Mirum Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mirum Pharmaceuticals, Inc.
The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.
With Bylvay approved last year for progressive familial intrahepatic cholestasis, Albireo looks to add an estimated 25,000 addressable patients to IBAT inhibitor’s label with strong Phase III data in ALGS.
Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.
Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.
- Specialty Pharmaceuticals